These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 12068161)
1. Local tissue toxicity in response to extravascular extravasation of magnetic resonance contrast media. Runge VM; Dickey KM; Williams NM; Peng X Invest Radiol; 2002 Jul; 37(7):393-8. PubMed ID: 12068161 [TBL] [Abstract][Full Text] [Related]
2. Cardiovascular responses after ionic and nonionic magnetic resonance contrast media in rats with acute myocardial infarction. Li HT; Saeed M; Wendland MF; Higgins CB Invest Radiol; 1993 Jan; 28(1):11-9. PubMed ID: 8425847 [TBL] [Abstract][Full Text] [Related]
3. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Tweedle MF; Wedeking P; Kumar K Invest Radiol; 1995 Jun; 30(6):372-80. PubMed ID: 7490190 [TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity of iodinated and gadolinium-based contrast agents in renal tubular cells at angiographic concentrations: in vitro study. Heinrich MC; Kuhlmann MK; Kohlbacher S; Scheer M; Grgic A; Heckmann MB; Uder M Radiology; 2007 Feb; 242(2):425-34. PubMed ID: 17179401 [TBL] [Abstract][Full Text] [Related]
5. Comparison of cardiovascular changes after administration of gadodiamide injection and gadopentetate dimeglumine in dogs. Bøkenes J; Hustvedt SO; Refsum H Acad Radiol; 1997 Mar; 4(3):204-9. PubMed ID: 9084778 [TBL] [Abstract][Full Text] [Related]
6. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Harpur ES; Worah D; Hals PA; Holtz E; Furuhama K; Nomura H Invest Radiol; 1993 Mar; 28 Suppl 1():S28-43. PubMed ID: 8486501 [TBL] [Abstract][Full Text] [Related]
7. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents. Lohrke J; Frisk AL; Frenzel T; Schöckel L; Rosenbruch M; Jost G; Lenhard DC; Sieber MA; Nischwitz V; Küppers A; Pietsch H Invest Radiol; 2017 Jun; 52(6):324-333. PubMed ID: 28323657 [TBL] [Abstract][Full Text] [Related]
8. Extravascular toxicity of two magnetic resonance contrast agents. Preliminary experience in the rat. Cohan RH; Leder RA; Herzberg AJ; Hedlund LW; Wheeler CT; Beam CA; Nadel SN; Dunnick NR Invest Radiol; 1991 Mar; 26(3):224-6. PubMed ID: 2055727 [TBL] [Abstract][Full Text] [Related]
9. Acute cardiotoxicity of gadolinium-based contrast media: findings in the isolated rat heart. Akre BT; Dunkel JA; Hustvedt SO; Refsum H Acad Radiol; 1997 Apr; 4(4):283-91. PubMed ID: 9110026 [TBL] [Abstract][Full Text] [Related]
10. Comparison of nephrotoxicity between two gadolinium-contrasts, gadodiamide and gadopentetate in patients with mildly diminished renal failure. Naito S; Tazaki H; Okamoto T; Takeuchi K; Kan S; Takeuchi Y; Kamata K J Toxicol Sci; 2017; 42(3):379-384. PubMed ID: 28496044 [TBL] [Abstract][Full Text] [Related]
11. Acute hemodynamic effects of recently developed monomer and dimer magnetic resonance imaging contrast media: a comparative study. Geschwind JF; Saeed M; Wendland MF; Szolar D; Derugin N; Higgins CB Acad Radiol; 1996 Aug; 3(8):667-77. PubMed ID: 8796731 [TBL] [Abstract][Full Text] [Related]
12. Gadolinium magnetic resonance contrast agents produce analytic interference in multiple serum assays. Proctor KA; Rao LV; Roberts WL Am J Clin Pathol; 2004 Feb; 121(2):282-92. PubMed ID: 14983944 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular effects caused by rapid administration of gadoversetamide injection in anesthetized dogs. Wible JH; Galen KP; Wojdyla JK Invest Radiol; 2001 May; 36(5):292-8. PubMed ID: 11394361 [TBL] [Abstract][Full Text] [Related]
14. Incidence of immediate gadolinium contrast media reactions. Prince MR; Zhang H; Zou Z; Staron RB; Brill PW AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854 [TBL] [Abstract][Full Text] [Related]
15. Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. Edward M; Quinn JA; Burden AD; Newton BB; Jardine AG Radiology; 2010 Sep; 256(3):735-43. PubMed ID: 20663970 [TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance contrast agents in neuroimaging. New agents and applications. Runge VM; Kirsch JE; Wells JW; Dunworth JN; Awh MH; Bittner DF Neuroimaging Clin N Am; 1994 Feb; 4(1):175-83. PubMed ID: 8130948 [TBL] [Abstract][Full Text] [Related]
17. MR diagnosis of head and neck tumors: comparison of contrast enhancement with triple-dose gadodiamide and standard-dose gadopentetate dimeglumine in the same patients. Vogl TJ; Mack MG; Juergens M; Stark M; Pegios W; Bergman C; Grevers G; Western A AJR Am J Roentgenol; 1994 Aug; 163(2):425-32. PubMed ID: 8037044 [TBL] [Abstract][Full Text] [Related]
18. Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA's Pharmacovigilance and Risk Assessment Committee Recommendation for Suspension of the Marketing Authorizations for 4 Linear Agents. Runge VM Invest Radiol; 2017 Jun; 52(6):317-323. PubMed ID: 28368880 [TBL] [Abstract][Full Text] [Related]
19. Hemodynamic effects of gadodiamide injection and gadopentetate dimeglumine in anesthetized dogs. Peters JL; Shaw DD Acta Radiol; 1993 Sep; 34(5):510-6. PubMed ID: 8369191 [TBL] [Abstract][Full Text] [Related]
20. Neurotoxic potential of gadodiamide after injection into the lateral cerebral ventricle of rats. Ray DE; Holton JL; Nolan CC; Cavanagh JB; Harpur ES AJNR Am J Neuroradiol; 1998 Sep; 19(8):1455-62. PubMed ID: 9763378 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]